期刊文献+

血浆置换治疗儿童血栓性微血管病的临床效果

Clinical Effect of Plasma Replacement in the Treatment of Thrombotic Microvascular Disease in Children
暂未订购
导出
摘要 目的 探讨血浆置换治疗儿童血栓性微血管病的效果.方法 选取2017年6月-2018年6月我院收治的儿童血栓性微血管病患者46例,随机分为两组,对照组应用皮质激素治疗,研究组在皮质激素应用的基础上加用血浆置换冶疗.结果 临床治疗效果:研究组vs对照组为94.1% (32/34) vs 67.6% (23/34)(P<0.05).结论 血浆置换在儿童血栓性微血管病的治疗中,可显著提高临床治疗的效果. Objective To investigate the effect of plasma replacement in the treatment of thrombotic microvascular disease in children.Methods 46 cases of children with thrombotic microvascular disease in our hospital from June 2017 to June 2018 were randomly divided into two groups,the control group was treated with corticosteroid therapy,and the study group added plasma replacement Metallurgy therapy on the basis of corticosteroid application.Results The effect of clinical therapy was 94.1%(32/34)vs 67.6%(23/34)(p<0.05)in the Study Group vs control group.Conclusion Plasma replacement can significantly improve the effect of clinical treatment in the treatment of thrombotic microvascular disease in children.
作者 王超 WANG Chao(Hubei Gucheng People's Hospital pediatrics,Gucheng,441700,China)
出处 《血栓与止血学》 2019年第1期21-22,26,共3页 Chinese Journal of Thrombosis and Hemostasis
关键词 血浆置换 血栓性微血管病 Plasma replacement Thrombotic microvascular disease
  • 相关文献

参考文献7

二级参考文献43

  • 1Tao Han,Ying Liu,Huan Liu,Zheng-Yan Zhu,Yan Li,Shi-Xiang Xiao,Zhen Guo,Zhen-Gang Zhao,Department of Hepatology,Tianjin Institute of Hepatobiliary Disease,Tianjin Key Laboratory of Artificial Cells,Tianjin Third Central Hospital,Tianjin Medical University,83 Jintang Road,Tianjin 300170, China.Serum thymosin β4 levels in patients with hepatitis B virus-related liver failure[J].World Journal of Gastroenterology,2010,16(5):625-630. 被引量:21
  • 2Tsai HM. Pathophysiology of thrombotic thrombocytope- nic purpura[J]. Int J Hematol,2010,91(1) :1-19.
  • 3Jiang HH,An XJ,Li Y,et al. Clinical features and prog- nostic factors of thrombotic thrombocytopenic purpura as- sociated with systemic lupus erythematosus: a literature review of 105 cases from 1999 to 2011[J]. Clin Rheuma toi,2014,33(3) :419-427.
  • 4Thompson CE, Damon IrE, Ries CA, et al. Thrombotic mi- croangiopathies in the 1980s: clinical features, response to treatment, and the impact of the human immunodeficiency vi- rus epidemic[J]. Blood, 1992,80(8) : 1890-1895.
  • 5Kyttaris VC. Targeting B cells in severe thrombotic thrombo- cytopenic purpura-a road to eure[J]. Crit Care Med, 2012,40 (1) :317- 318.
  • 6Daram SR,Philipneri M, Puri N, et al. Thromboticthrom- bocytopenic purpura without schistoeytes on the peripher- al blood smear[J]. South Med J,2005,98(3):392-395.
  • 7Burns ER,Lou Y. Morphological diagnosis of the throm boticthrombocytopenic purpura[J]. Am J Hematol, 2004, 75(1):18- 21.
  • 8Scully M,Goodship T. How I treat thrombotic thrombo eytopenic purpura andatypical haemolytic uraemic syn- drome[J]. Br J of Hematol,2014,164(6):759-766.
  • 9Yang SB,Jin M, Lin SL, et al. ADAMTS18 activity and antigen during therapy and follow-up of patients with idi- opathic thrombotic thrombocytopenic purpura:correlation with clinical outcome[J]. Haematol Hematol J, 2011,96 (10) : 1521-1527.
  • 10Bennett1 CL, Jacob S, Dunn BL, et al. Ticlopidine-associ- ated ADAMTS18 activity deficient thrombotic thrombo- cytopenic purpura in 22 persons in Japan: a report from the Southern Network on Adverse Reactions(SONAR)[J]. Br J Haematol,2018,161(6):896- 898.

共引文献43

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部